Somaxon Pharmaceuticals (SOMX) Posts Q4 Loss of 21c/Share, Inline with the Street
Tweet
Share
E-mailGet Alerts SOMX Hot Sheet
Price: $3.00 --0%
Financial Fact:
Basic and diluted net loss per share: -0.65
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Basic and diluted net loss per share: -0.65
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) reported Q4 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.42 million.
Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.
For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.
Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.
For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance
- zSpace, Inc. (ZSPC) Reports Q2 results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
